{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06112314",
            "orgStudyIdInfo": {
                "id": "IMC-F106C-301"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-505306-42-00",
                    "type": "OTHER",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "Immunocore Ltd",
                "class": "INDUSTRY"
            },
            "briefTitle": "IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)",
            "officialTitle": "A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301",
            "acronym": "PRISM-MEL-301",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "imc-regimen-versus-nivolumab-regimens-in-previously-untreated-advanced-melanoma-prism-mel"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-12-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-19",
            "studyFirstSubmitQcDate": "2023-10-31",
            "studyFirstPostDateStruct": {
                "date": "2023-11-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Immunocore Ltd",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A\\*02:01-positive participants with previously untreated advanced melanoma."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Melanoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 680,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm A: IMC-F106C Low Dose + Nivolumab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive IMC-F106C Low Dose once weekly (QW) for the first 12 weeks, then every 2 weeks (Q2W) through Week 51, and then every 4 weeks (Q4W) until Week 101. Nivolumab is given Q4W until Week 101.",
                    "interventionNames": [
                        "Biological: IMC-F106C",
                        "Biological: Nivolumab"
                    ]
                },
                {
                    "label": "Arm B: IMC-F106C High Dose + Nivolumab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive IMC-F106C High Dose QW for the first 12 weeks, then Q2W through Week 51, and then Q4W until Week 101. Nivolumab is given Q4W until Week 101.",
                    "interventionNames": [
                        "Biological: IMC-F106C",
                        "Biological: Nivolumab"
                    ]
                },
                {
                    "label": "Arm C: Nivolumab OR Nivolumab + Relatlimab",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Participants receive nivolumab 480 mg monotherapy, or nivolumab 480 mg + relatlimab 160 mg, Q4W until Week 101.",
                    "interventionNames": [
                        "Biological: Nivolumab",
                        "Biological: Nivolumab + Relatlimab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "IMC-F106C",
                    "description": "Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.",
                    "armGroupLabels": [
                        "Arm A: IMC-F106C Low Dose + Nivolumab",
                        "Arm B: IMC-F106C High Dose + Nivolumab"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Nivolumab",
                    "description": "Concentrate for solution for infusion at a unit dose of 10 mg/mL.",
                    "armGroupLabels": [
                        "Arm A: IMC-F106C Low Dose + Nivolumab",
                        "Arm B: IMC-F106C High Dose + Nivolumab",
                        "Arm C: Nivolumab OR Nivolumab + Relatlimab"
                    ],
                    "otherNames": [
                        "OPDIVO"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Nivolumab + Relatlimab",
                    "description": "Concentrate for solution for infusion at a unit dose of 10 mg/mL.",
                    "armGroupLabels": [
                        "Arm C: Nivolumab OR Nivolumab + Relatlimab"
                    ],
                    "otherNames": [
                        "OPDUALAG"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression-Free Survival (PFS)",
                    "description": "PFS as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumours (RECIST 1.1).",
                    "timeFrame": "Up to ~24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall Survival (OS)",
                    "description": "OS is the time from randomization to time of death from any cause.",
                    "timeFrame": "Up to ~24 months"
                },
                {
                    "measure": "Overall Response Rate (ORR)",
                    "description": "ORR as assessed by BICR according to RECIST 1.1.",
                    "timeFrame": "Up to ~24 months"
                },
                {
                    "measure": "Number of Participants Experiencing \u22651 Adverse Event (AE)",
                    "description": "An AE is defined as the appearance of (or worsening of any pre-existing) undesirable sign, symptom, or medical condition that occur in the study.",
                    "timeFrame": "Up to ~36 months"
                },
                {
                    "measure": "Number of Participants Experiencing \u22651 Serious Adverse Event (SAE)",
                    "description": "An SAE is any untoward medical consequence that results in death; requires inpatient hospitalization or prolongs existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or any other important medical event in the opinion of the Investigator.",
                    "timeFrame": "Up to ~36 months"
                },
                {
                    "measure": "Number of Participants Experiencing a Dose Interruption, Reduction, or Discontinuation",
                    "description": "The number of participants with a dose interruption, reduction, or discontinuation due to AE will be reported.",
                    "timeFrame": "Up to ~24 months"
                },
                {
                    "measure": "Maximum Plasma Concentration (Cmax) of IMC-F106C",
                    "description": "The Cmax of IMC-F106C will be reported.",
                    "timeFrame": "Day 1 of Weeks 1, 2, and 3: Predose and 0.5 and 4 hours postdose"
                },
                {
                    "measure": "Incidence of anti-IMC-F106C Antibodies",
                    "description": "The incidence of anti-IMC-F106C antibodies, including neutralizing antibodies, will be reported.",
                    "timeFrame": "Up to ~24 months"
                },
                {
                    "measure": "Association between PFS and Intra-Tumor Immune Cells",
                    "description": "The potential association between the effect of IMC-F106C on efficacy and intra-tumor environment will be explored. Intra-tumor environment is estimated as the ratio of CD3+ to CD163+ cells and the correlation with PFS will be estimated by the hazard ratio (+/- 95% CI) from a Cox model. This analysis will be restricted to subjects randomized to receive IMC-F106C.",
                    "timeFrame": "Up to ~24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants must be HLA-A\\*02:01-positive\n* Participants must have histologically confirmed Stage IV or unresectable Stage III melanoma\n* Archived or fresh tumor tissue sample that must be confirmed as adequate\n* Participants must have measurable disease per RECIST 1.1\n* Participant must have BRAF V600 mutation status determined\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the study screening date until 5 months after the final dose of study intervention\n\nExclusion Criteria:\n\n* Participants with a history of a malignant disease other than those being treated in this study\n* Participants with untreated, active, or symptomatic central nervous system (CNS) metastases or carcinomatous meningitis\n* Hypersensitivity to IMC-F106C, nivolumab, relatlimab, or any associated excipients\n* Participants with clinically significant pulmonary disease or impaired lung function\n* Participants with clinically significant cardiac disease or impaired cardiac function\n* Participants with active autoimmune disease requiring immunosuppressive treatment\n* Participants with any medical condition that is poorly controlled or that would, in the Investigator's or Sponsor's judgment, adversely impact the participant's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results\n* Participants who received prior systemic anticancer therapy for unresectable or metastatic melanoma\n* Participants with a history of a life-threatening AE related to prior anti-PD-(L)1 or anti-LAG-3",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Immunocore Medical Information",
                    "role": "CONTACT",
                    "phone": "844-466-8661",
                    "email": "medical.information@immunocore.com"
                },
                {
                    "name": "Immunocore Medical Information EU",
                    "role": "CONTACT",
                    "phone": "+00 800-744-51111",
                    "email": "medinfo.eu@immunocore.com"
                }
            ],
            "locations": [
                {
                    "facility": "The Angeles Clinic and Research Institute- West Los Angeles",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90025",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "UCLA Hematology/Oncology",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of Colorado, Anschutz Medical Campus",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "Columbia University Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Thomas Jefferson University",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19107",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "UPMC Hillman Cancer Center",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Prisma Health Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Greenville",
                    "state": "South Carolina",
                    "zip": "29605",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lisa Johnson",
                            "role": "CONTACT",
                            "email": "Lisa.johnson@prismahealth.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.85262,
                        "lon": -82.39401
                    }
                },
                {
                    "facility": "Gallipoli Medical Research Foundation (Greenslopes Private Hospital)",
                    "status": "RECRUITING",
                    "city": "Greenslopes",
                    "state": "Queensland",
                    "zip": "4120",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Gallipoli Research",
                            "role": "CONTACT",
                            "phone": "+61 7 3394 7284",
                            "email": "Enquiries.GMR@gallipoliresearch.org.au"
                        }
                    ],
                    "geoPoint": {
                        "lat": -27.50815,
                        "lon": 153.04951
                    }
                },
                {
                    "facility": "University of Sydney - Melanoma Institute Australia (MIA) - The Poche Centre",
                    "status": "RECRUITING",
                    "city": "Wollstonecraft",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.8328,
                        "lon": 151.18981
                    }
                },
                {
                    "facility": "The University of Queensland (UQ) - Princess Alexandra Hospital (PAH)",
                    "status": "RECRUITING",
                    "city": "Woolloongabba",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -27.48855,
                        "lon": 153.03655
                    }
                },
                {
                    "facility": "Universit\u00e4tsklinikum St. P\u00f6lten",
                    "status": "RECRUITING",
                    "city": "P\u00f6lten",
                    "country": "Austria",
                    "geoPoint": {
                        "lat": 48.2,
                        "lon": 15.63333
                    }
                },
                {
                    "facility": "Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Ambroise-Pare",
                    "status": "RECRUITING",
                    "city": "Boulogne-Billancourt",
                    "zip": "92104",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.83333,
                        "lon": 2.25
                    }
                },
                {
                    "facility": "Institut Gustave Roussy (IGR) Service de Dermatolgie",
                    "status": "RECRUITING",
                    "city": "Villejuif",
                    "zip": "94800",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "Universitaetsklinikum Heidelberg (UKHD) - Hautklinik",
                    "status": "RECRUITING",
                    "city": "Heidelberg",
                    "zip": "69120",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 49.40768,
                        "lon": 8.69079
                    }
                },
                {
                    "facility": "Istituto Nazionale Tumori (INT) \"Fondazione G. Pascale\" di Napoli",
                    "status": "RECRUITING",
                    "city": "Napoli",
                    "zip": "80131",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 40.85216,
                        "lon": 14.26811
                    }
                },
                {
                    "facility": "Istituto Oncologico Veneto (IOV) IRCCS",
                    "status": "RECRUITING",
                    "city": "Padova",
                    "zip": "I-35128",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.40797,
                        "lon": 11.88586
                    }
                },
                {
                    "facility": "Klinika Onkologii i Radioterapii Uniwersyteckie Centrum Kliniczne",
                    "status": "RECRUITING",
                    "city": "Gdansk",
                    "zip": "80-214",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 54.35205,
                        "lon": 18.64637
                    }
                },
                {
                    "facility": "Klinika Nowotwor\u00f3w Tkanek Mi\u0119kkich, Ko\u015bci i Czerniak\u00f3w",
                    "status": "RECRUITING",
                    "city": "Warszawa",
                    "zip": "02-781",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 52.22977,
                        "lon": 21.01178
                    }
                },
                {
                    "facility": "Hospital Universitario Ramon y Cajal",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28034",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario Virgen del Rocio",
                    "status": "RECRUITING",
                    "city": "Sevilla",
                    "zip": "41013",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 37.38283,
                        "lon": -5.97317
                    }
                },
                {
                    "facility": "UniversitaetsSpital Zuerich - Dermatologische Klinik",
                    "status": "RECRUITING",
                    "city": "Zurich",
                    "zip": "8901",
                    "country": "Switzerland",
                    "geoPoint": {
                        "lat": 47.36667,
                        "lon": 8.54999
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "removedCountries": [
                "Argentina",
                "Belgium",
                "Brazil",
                "Canada",
                "Mexico",
                "Romania",
                "United Kingdom"
            ]
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008545",
                    "term": "Melanoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000018326",
                    "term": "Nevi and Melanomas"
                },
                {
                    "id": "D000012878",
                    "term": "Skin Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "asFound": "Melanoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12448",
                    "name": "Nevus, Pigmented",
                    "relevance": "LOW"
                },
                {
                    "id": "M12446",
                    "name": "Nevus",
                    "relevance": "LOW"
                },
                {
                    "id": "M20470",
                    "name": "Nevi and Melanomas",
                    "relevance": "LOW"
                },
                {
                    "id": "M15681",
                    "name": "Skin Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077594",
                    "term": "Nivolumab"
                },
                {
                    "id": "C000721227",
                    "term": "Relatlimab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1854",
                    "name": "Nivolumab",
                    "asFound": "Technique",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M354150",
                    "name": "Relatlimab",
                    "asFound": "Episodic",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19201",
                    "name": "Muromonab-CD3",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                }
            ]
        }
    },
    "hasResults": false
}